We understand that this proposed mechanism could be just one of the many plausible scenarios explaining resistance to EGFR-targeted therapies since alternative escape routes such as TGF-β and IL-6 axis have been implicated in other tumour types (Yao et al, 2010). This evidence concerns the gene TGFB1 and neoplasm.